Novartis set to release Entresto heart failure drug
BASEL, Switzerland — Novartis has received Food and Drug Administration approval for Entresto (sacubitril/valsartan) tablets, a medication for heart failure with reduced injection fraction. An angiotensin receptor neprilysin inhibitor (ARNI), Entresto reduces the strain on a failing heart. The twice-a-day tablet acts to enhance the protective neurohormonal systems of the heart while simultaneously suppressing the
